


Novel nuclear medicine to advance patient care with focus on Actinium-225

Targeted Alpha Therapy: the JRC Experience


Maria Betti

European Commission, JRC, Directorate G for Nuclear Safety and Security, Director
SAMIRA Conference , 20th March 2018

Prostate Cancer Incidence





Prostate Cancer Mortality



307,000 deaths

6.6% total men deaths

Targeted Therapy



Selective killing tumor cells

Limited side effects (healthy tissue)




^{225}Ac -PSMA617 Treatment Results



April 2017

PSA = 2280 ng/ml

1 x
 ^{225}Ac -PSMA
→
(10 MBq)



July 2017

PSA = 205 ng/ml

Looking forward to the future



- Follow-up Clinical trials
- Specific Regulations
- Pharmaceutical Industry Involvement



Thank you

Any questions?

You can find me at maria.betti@ec.europa.eu